Literature DB >> 15362753

Pathological changes of advanced lower-rectal cancer by preoperative radiotherapy.

Hirokatsu Kinoshita1, Toshiaki Watanabe, Akio Yanagisawa, Hirokazu Nagawa, Yo Kato, Tetsuichiro Muto.   

Abstract

BACKGROUND/AIMS: In the treatment of lower rectal cancer, we examined the pathological effects of preoperative radiotherapy on intramural spread of tumor and risk factors for local recurrence, including tumor deposit, budding growth of primary tumors, and micrometastasis to lymph nodes.
METHODOLOGY: Ninety-four patients who underwent surgery for lower rectal cancer were selected. Forty-seven patients received preoperative radiotherapy, at a total dose of 50 Gy [Rad(+) group], whereas 47 did not [Rad(-) group]. Intramural spread was evaluated between the Rad(+) and Rad(-) groups. For analysis of tumor deposit, budding, and micrometastasis, 25 stage-matched patients were selected in both groups.
RESULTS: Intramural spread was significantly less in the Rad(+) group, compared with the Rad(-) group. The Rad(+) group showed a significant decrease in tumor deposit, budding, and micrometastasis, compared with the Rad(-) group. In patients having overt lymph node metastases or not, the tumor deposit and budding were significantly higher in patients having overt metastases, compared with those not having them, in the Rad(-) group, whereas there was no significant difference in the Rad(+) group.
CONCLUSIONS: Intramural spread and tumor deposit, budding, and micrometastasis were significantly decreased in the Rad(+) group, compared with the Rad(-) group. These results suggested effects of preoperative radiotherapy for sphincter preservation, as well as for decreasing the local recurrence rate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15362753

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  6 in total

Review 1.  Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Authors:  Alessandro Lugli; Richard Kirsch; Yoichi Ajioka; Fred Bosman; Gieri Cathomas; Heather Dawson; Hala El Zimaity; Jean-François Fléjou; Tine Plato Hansen; Arndt Hartmann; Sanjay Kakar; Cord Langner; Iris Nagtegaal; Giacomo Puppa; Robert Riddell; Ari Ristimäki; Kieran Sheahan; Thomas Smyrk; Kenichi Sugihara; Benoît Terris; Hideki Ueno; Michael Vieth; Inti Zlobec; Phil Quirke
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

Review 2.  Microscopic intramural extension of rectal cancer after neoadjuvant chemoradiation: A meta-analysis based on individual patient data.

Authors:  An-Sofie Verrijssen; José Guillem; Rodrigo Perez; Krzysztof Bujko; Nathalie Guedj; Angelita Habr-Gama; Ruud Houben; Danny Goudkade; Jarno Melenhorst; Jeroen Buijsen; Ben Vanneste; Heike I Grabsch; Murillo Bellezzo; Gabriel Paiva Fonseca; Frank Verhaegen; Maaike Berbee; Evert J Van Limbergen
Journal:  Radiother Oncol       Date:  2019-11-09       Impact factor: 6.280

Review 3.  Is the 1-cm rule of distal bowel resection margin in rectal cancer based on clinical evidence? A systematic review.

Authors:  Krzysztof Bujko; Andrzej Rutkowski; George J Chang; Wojciech Michalski; Ewa Chmielik; Jerzy Kusnierz
Journal:  Ann Surg Oncol       Date:  2011-08-31       Impact factor: 5.344

4.  Multivisceral resection for locally advanced rectal cancer: adequate length of distal resection margin.

Authors:  Hyo Kang; Ho Goon Kim; Jae Kyun Ju; Dong Yi Kim
Journal:  J Korean Surg Soc       Date:  2012-01-27

5.  Poor prognostic and staging value of tumor deposit in locally advanced rectal cancer with neoadjuvant chemoradiotherapy.

Authors:  Yaqi Wang; Jing Zhang; Menglong Zhou; Lifeng Yang; Juefeng Wan; Lijun Shen; Liping Liang; Ye Yao; Hui Zhang; Zhen Zhang
Journal:  Cancer Med       Date:  2019-02-21       Impact factor: 4.452

Review 6.  Ultimate Functional Preservation With Intersphincteric Resection for Rectal Cancer.

Authors:  Maxime Collard; Jérémie H Lefevre
Journal:  Front Oncol       Date:  2020-03-05       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.